Haibo Shen

2.4k total citations
79 papers, 1.8k citations indexed

About

Haibo Shen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Electrical and Electronic Engineering. According to data from OpenAlex, Haibo Shen has authored 79 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Molecular Biology and 15 papers in Electrical and Electronic Engineering. Recurrent topics in Haibo Shen's work include Bladder and Urothelial Cancer Treatments (9 papers), Semiconductor materials and devices (8 papers) and Ferroelectric and Piezoelectric Materials (6 papers). Haibo Shen is often cited by papers focused on Bladder and Urothelial Cancer Treatments (9 papers), Semiconductor materials and devices (8 papers) and Ferroelectric and Piezoelectric Materials (6 papers). Haibo Shen collaborates with scholars based in China, United States and Germany. Haibo Shen's co-authors include Raphael Tsu, Mitra Dutta, Hong Fan, J Kao, David E. Kotecki, J. D. Baniecki, R. B. Laibowitz, J Ryan, Yinjie Zhou and T. M. Shaw and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Haibo Shen

70 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haibo Shen China 20 585 573 508 338 273 79 1.8k
Yi‐Hsuan Hsiao Taiwan 28 545 0.9× 960 1.7× 719 1.4× 465 1.4× 266 1.0× 120 2.8k
Yu‐An Chen China 22 556 1.0× 340 0.6× 255 0.5× 160 0.5× 219 0.8× 74 1.6k
Philip Lee United States 27 1.0k 1.8× 369 0.6× 283 0.6× 240 0.7× 192 0.7× 70 3.8k
Jun Hwan Kim South Korea 28 725 1.2× 883 1.5× 192 0.4× 212 0.6× 148 0.5× 178 2.7k
Hua Liu China 24 1.0k 1.7× 220 0.4× 273 0.5× 192 0.6× 378 1.4× 107 2.2k
I‐Chun Chen Taiwan 23 415 0.7× 247 0.4× 186 0.4× 251 0.7× 269 1.0× 104 1.9k
Huageng Liang China 26 772 1.3× 345 0.6× 147 0.3× 909 2.7× 252 0.9× 92 1.9k
Beilei Wang China 26 536 0.9× 561 1.0× 182 0.4× 441 1.3× 63 0.2× 126 2.4k
Chan Li China 19 409 0.7× 469 0.8× 364 0.7× 540 1.6× 172 0.6× 77 1.8k
Jing Zhong China 28 707 1.2× 141 0.2× 488 1.0× 824 2.4× 148 0.5× 149 2.5k

Countries citing papers authored by Haibo Shen

Since Specialization
Citations

This map shows the geographic impact of Haibo Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haibo Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haibo Shen more than expected).

Fields of papers citing papers by Haibo Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haibo Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haibo Shen. The network helps show where Haibo Shen may publish in the future.

Co-authorship network of co-authors of Haibo Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Haibo Shen. A scholar is included among the top collaborators of Haibo Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haibo Shen. Haibo Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Zhang, Shun, et al.. (2023). Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line. Pharmacogenomics and Personalized Medicine. Volume 16. 219–228. 1 indexed citations
5.
Zhang, Liangqi, et al.. (2022). Efficient CNN Architecture Design Guided by Visualization. 2022 IEEE International Conference on Multimedia and Expo (ICME). 1–6. 9 indexed citations
6.
Wu, Bo, Xin Lü, Haibo Shen, et al.. (2020). Intratumoral heterogeneity and genetic characteristics of prostate cancer. International Journal of Cancer. 146(12). 3369–3378. 33 indexed citations
7.
Wang, Chen, Yu Ding, Yuanyong Liu, et al.. (2020). Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation. Frontiers in Immunology. 11. 576603–576603. 7 indexed citations
8.
Wu, Yu, et al.. (2020). The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia. World Journal of Urology. 38(11). 2923–2931. 5 indexed citations
9.
Wu, Yu, et al.. (2020). Urinary kidney injury molecule-1: a novel biomarker to monitor renal function in patients with unilateral ureteral obstruction. International Urology and Nephrology. 52(11). 2065–2072. 5 indexed citations
10.
Xu, Ding, et al.. (2019). Variation of prostatic morphology in Chinese benign prostatic hyperplasia patients of different age decades. The Aging Male. 23(5). 457–463. 7 indexed citations
11.
Yao, Yuanshan, et al.. (2019). CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p/SIRT1 axis and activating Wnt/β-catenin signaling pathway. Biomedicine & Pharmacotherapy. 111. 1367–1375. 71 indexed citations
12.
Rao, Chuangzhou, Guofang Zhao, Chen Zhang, et al.. (2019). MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomedicine & Pharmacotherapy. 114. 108662–108662. 23 indexed citations
13.
Wu, Lei, Jian Cao, Zhongchen Yang, et al.. (2018). OA07 Clinical Characterization Of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers. Journal of Thoracic Oncology. 13(12). S1046–S1047.
14.
Liu, Zhefeng, Lin Wu, Jun Cao, et al.. (2018). Clinical characterization of <em>ERBB2</em> exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients. OncoTargets and Therapy. Volume 11. 7323–7331. 27 indexed citations
15.
Shen, Haibo, et al.. (2015). Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer. International Urology and Nephrology. 47(3). 479–484. 2 indexed citations
16.
Wang, Ning, et al.. (2015). TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells. Cancer Biotherapy and Radiopharmaceuticals. 30(2). 87–93. 20 indexed citations
17.
Shen, Haibo, Jingli Xie, & Hongyan Lu. (2013). Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis. Climacteric. 17(4). 319–324. 21 indexed citations
18.
Shen, Haibo, et al.. (2012). In vitro study on the binding of gemcitabine to bovine serum albumin. Journal of Pharmaceutical and Biomedical Analysis. 75. 86–93. 85 indexed citations
19.
Qi, Jun, Zhengqin Gu, Fang Chen, et al.. (2010). Management of Renal Cell Carcinoma With Tumor Thrombus in Renal Vein and the Inferior Vena Cava. Annals of Vascular Surgery. 24(8). 1089–1093. 7 indexed citations
20.
Baniecki, J. D., R. B. Laibowitz, T. M. Shaw, et al.. (1999). Effects of annealing conditions on charge loss mechanisms in MOCVD Ba0·7Sr0·3TiO3 thin film capacitors. Journal of the European Ceramic Society. 19(6-7). 1457–1461. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yi‐Hsuan Hsiao Breakdown of academic impact, for papers by Yu‐An Chen Breakdown of academic impact, for papers by Philip Lee Breakdown of academic impact, for papers by Jun Hwan Kim Breakdown of academic impact, for papers by Hua Liu Breakdown of academic impact, for papers by I‐Chun Chen Breakdown of academic impact, for papers by Huageng Liang Breakdown of academic impact, for papers by Beilei Wang Breakdown of academic impact, for papers by Chan Li Breakdown of academic impact, for papers by Jing Zhong
Rankless by CCL
2026